All In Biotech

Drug Trial Radar · NCT03778931

Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial

Last checked: Nov 19, 2026Latest source record: Sep 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 478 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

478

Actual

Start

May 10, 2019

Primary completion

Aug 24, 2021

Study completion Aug 22, 2024

Sponsor

Lead sponsor
Stemline Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Dec 19, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3 clinical study compares the efficacy and safety of elacestrant to the standard of care (SoC) options of fulvestrant or an aromatase inhibitor (AI) in women and men with breast cancer whose disease has advanced on at least one endocrine therapy including a CDK4/6 inhibitor in combination with fulvestrant or an aromatase inhibitor (AI).

Conditions

  • Breast Cancer

Interventions

  • ElacestrantDrug

    400 mg/day once daily oral dosing

  • Standard of CareDrug

    * Fulvestrant: 500 mg administered intramuscularly (IM) into the buttocks as two 5 mL injections on C1D1, C1D15 and C2D1 and Day 1 of every subsequent 28-day cycle * Anastrozole 1 mg/day on a continuous dosing schedule * Letrozole: 2.5 mg/day on a continuous dosing schedule * Exemestane: 25 mg/day on a continuous dosing schedule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival in ESR1-mut ParticipantsTime frame: From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)
  2. Progression-free Survival in All ParticipantsTime frame: From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)

Locations

244 sites in 17 countries. Site status is shown where the registry gives one.

  • The University of Arizona Cancer Center

    Tucson, Arizona

  • St Bernard's Cancer Care

    Jonesboro, Arkansas

  • St. Jude Heritage Healthcare

    Fullerton, California

  • Adventist Health Glendale

    Glendale, California

  • Moores Cancer Center at UC San Diego Health

    La Jolla, California

  • Keck Hospital of USC-Norris Healthcare (HC3), Investigational Drug Service (IDS)

    Los Angeles, California

  • Keck Medical Center of USC

    Los Angeles, California

  • USC IDS Pharmacy

    Los Angeles, California

  • UCLA Hematology/Oncology

    Los Angeles, California

  • UCLA West Medical Pharmacy 159

    Los Angeles, California

  • TMPN Cancer Care

    Redondo Beach, California

  • UC Davis Medical Center, Investigational Drug Service

    Sacramento, California

  • UCSF Medical Center

    San Francisco, California

  • Ridley-Tree Cancer Center

    Santa Barbara, California

  • Anschutz Cancer Center Pavilion

    Aurora, Colorado

  • US Oncology - Rocky Mountain Cancer Centers - Midtown

    Denver, Colorado

  • Poudre Valley Health Care, Inc. d/b/a Poudre Valley Health System

    Fort Collins, Colorado

  • UCHealth Cancer Center

    Fort Collins, Colorado

  • Yale Cancer Center

    New Haven, Connecticut

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia

  • Orlando Health Cancer Institute

    Orlando, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Piedmont Cancer Institute, P.C. - Oncology

    Atlanta, Georgia

  • Suburban Hematology-Oncology Associates

    Lawrenceville, Georgia

  • Northwest Georgia Oncology Centers

    Marietta, Georgia

  • Chicago Association for Research and Education in Science

    Chicago, Illinois

  • Rush University Cancer Center

    Chicago, Illinois

  • Cancer Care Center of Decatur

    Decatur, Illinois

  • Joliet Oncology-Hematology Associates

    Joliet, Illinois

  • Presence Medical Group Hematology Oncology

    Skokie, Illinois

  • Simmons Cancer Institute

    Springfield, Illinois

  • Healthcare Research Network II

    Tinley Park, Illinois

  • Fort Wayne Medical Oncology And Hematology

    Fort Wayne, Indiana

  • Goshen Center for Cancer Care

    Goshen, Indiana

  • Hematology Oncology Of Indiana

    Indianapolis, Indiana

  • Cancer Resource Centre

    Munster, Indiana

  • University of Kansas Cancer Center

    Westwood, Kansas

  • Norton Cancer Institute

    Louisville, Kentucky

  • Pikeville Medical Center - Oncology/Hematology

    Pikeville, Kentucky

  • Ochsner Medical Center

    New Orleans, Louisiana

Showing 40 of 244 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.